{"id":"ihl-42x-high-dose","_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"_scrapedAt":"2026-03-28T03:35:08.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123925,"model":"claude-sonnet-4-5-20250929"},"description":"IHL-42X High Dose is an investigational therapy being developed by Incannex Healthcare Ltd, currently in Phase 2 clinical trials. The drug's molecular target and specific mechanism of action have not been publicly disclosed. Limited information is available regarding its therapeutic applications and development status.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT06146101","phase":"PHASE2, PHASE3","title":"RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incannex Healthcare Ltd","startDate":"2024-05-02","conditions":"Obstructive Sleep Apnea","enrollment":560}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Phase 2 Investigational Product - IHL-42X High dose"],"phase":"phase_2","status":"active","brandName":"IHL-42X High Dose","genericName":"IHL-42X High Dose","companyName":"Incannex Healthcare Ltd","companyId":"incannex-healthcare-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}